We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

9863:HKEXZhejiang Leapmotor Technology Co., Ltd. Class H Analysis

Data as of 2026-03-14 - not real-time

HK$44.16

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Zhejiang Leapmotor (9863.HK) trades at HK$44.16, far below its DCF-derived fair value of HK$182.45, implying an estimated upside of roughly 81%. The stock is currently in a bearish price trend, sitting beneath its 20‑day (42.37) and 50‑day (44.14) SMAs, with a 30‑day volatility of 46.2% and a low beta of 0.19, indicating heightened price swings but limited market‑wide systematic risk. Technical signals are mixed: RSI sits at a neutral 56.6, while the MACD histogram is positive (0.45) despite the line being below the signal, hinting at a possible short‑term rebound toward the resistance level of HK$46.12. Fundamentals show a turnaround narrative – forward EPS of 3.09 and a forward P/E of 14.28 contrast sharply with the current loss‑making profile (trailing EPS –0.5, negative operating margin). The company recently announced a 2026 components and brand‑services pact, which could accelerate product rollout and improve margin visibility. With a solid cash base (HK$16.7 bn) and manageable debt (HK$3.0 bn), the balance sheet can support the anticipated growth.
Given the substantial valuation gap, improving earnings outlook, and strategic partnership, the stock presents a compelling long‑term investment case despite short‑term volatility. The risk profile is tempered by the company's strong liquidity and low systematic risk, though sector‑specific and regulatory headwinds in China’s auto industry remain. Investors should weigh the upside potential against the current bearish technical stance and the need for the company to convert its cash flow advantages into sustainable profitability.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bearish SMA positioning
  • Positive MACD histogram suggesting short‑term bounce
  • Recent components partnership may provide catalyst

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation upside versus DCF fair value
  • Forward EPS positivity and forward P/E around 14x
  • Strategic deal expected to improve margins and revenue growth

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term NEV industry tailwinds in China
  • Strong cash position and low debt supporting expansion
  • DCF valuation indicating substantial intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth174.10%
Profit Margin-1.21%
P/E Ratio14.3
ROE-4.91%
ROA-1.81%
Debt/Equity23.33
P/B Ratio4.0
Op. Cash FlowHK$11.1B
Free Cash FlowHK$6.6B

Technical Analysis

TrendBearish
RSI56.6
SupportHK$37.64
ResistanceHK$46.12
MA 20HK$42.37
MA 50HK$44.14
MA 200HK$55.06
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueHK$182.45
Target PriceHK$79.88
Upside/Downside80.89%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.19
Volatility46.23%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.